UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000021743 |
|---|---|
| Receipt number | R000025079 |
| Scientific Title | Analysis of predictive biomarker and analysis of correlations between toxicities and SNPs that can be related to pharmacokinetics, in ramucirumab plus paclitaxel therapy for elderly patients with unresectable or recurrent gastric cancer |
| Date of disclosure of the study information | 2016/04/01 |
| Last modified on | 2017/04/10 20:39:32 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Analysis of predictive biomarker and analysis of correlations between toxicities and SNPs that can be related to pharmacokinetics, in ramucirumab plus paclitaxel therapy for elderly patients with unresectable or recurrent gastric cancer
Acronym
Analysis of biomarker for ramucirumab plus paclitaxel therapy
Scientific Title
Analysis of predictive biomarker and analysis of correlations between toxicities and SNPs that can be related to pharmacokinetics, in ramucirumab plus paclitaxel therapy for elderly patients with unresectable or recurrent gastric cancer
Scientific Title:Acronym
Analysis of biomarker for ramucirumab plus paclitaxel therapy
Region
| Japan |
Condition
Condition
unresectable or recurrent gastric cancer
Classification by specialty
| Gastroenterology | Hematology and clinical oncology | Gastrointestinal surgery |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
To identify novel tissue or serum biomarkers, and SNPs, which can predict efficacy or toxicities in treatment of ramucirumab plus paclitaxel therapy for elderly patients with unresectable or recurrent colorectal cancer
Basic objectives2
Others
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
1. Tissue biomarkers including mutation, gene expression, and DNA methylation that correlate with efficacy from ramucirumab plus paclitaxel therapy
2. Serum biomarkers including mutation, gene expression, and DNA methylation that correlate with efficacy from ramucirumab plus paclitaxel therapy
3. SNPs that correlate with toxicities from ramucirumab plus paclitaxel therapy
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Diagnosis
Type of intervention
| Gene |
Interventions/Control_1
Nucleic acid from tumor tissues and serum
SNPs
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 70 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients are required to fulfill the following criteria for eligibility.
1) histologically confirmed as adenocarcinoma of the stomach
2) One or more evaluable lesions confirmed by CT or other imaging within 28 days before the registration.
3) ECOG performace status: 0-2.
4) Received only one previous chemotherapeutic regimen which is 5-FU-based (inluding patients who had recurrence during or within 24 weeks after adjuvant chemotherapy)
5) Estimated to survive for three months or more since registration.
6) Written informed consent.
7) Age 70 or above.
8) Fulfill the following hematological and biochemical data obtained in the most recent blood and urine tests. Neutrophils >= 1,500 /mm3, platelets >= 100,000 /mm3, hemoglobin >= 8.0 g/dl, AST =< 100 IU/l, ALT =< 100 IU/l, total bilirubin =< 1.5 g/dl, and creatinie =< 1.5 in blood test, and urine protein <= 1+ or 2 g/day. Patients should not receive transfusion or granulocyte colony stimulating factor within 14 days before the blood test.
9) Determined to be able to receive the study protocol by the responsible researcher or contributing researchers of this study.
Key exclusion criteria
Patients who fulfill the following criteria for exclusion are excluded.
1) Received taxane-based regimen.
2) Synchronous double cancer or past history of other cancer within 5 years, except curable carcinoma in situ and skin cancer.
3) Active infection and inflammation.
4) Active hepatitis.
5) Current or past history within 1 year of serious heart disease that requires hospitalization
6) Serious complications or severe complications that require hospitalization for therapy, such as gastrointestinal paresthesia, bowel obstruction, interstitial pneumonia, pulmonary fibrosis, uncontrollable hypertension, diabetes mellitus, renal dysfunction, liver dysfunction, and hepatic cirrhosis.
7) Active gastrointestinal bleeding.
8) Gastrointestinal perforation or histula, artelial embolism within 6 months or venous thromboembolism within 3 months before registration.
9) Receiving medications with psychotropic drugs for mental disorders, or having mental disorders that require medications with psychotropic drugs.
10) Grade 2 or more neuropathy.
11) Effusion that requires drainage.
12) Determined to be inappropriate to enter the study by the responsible researcher or contributing researchers, for any other reasons.
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Chikashi Ishioka |
Organization
Institute of Development, Aging and Cancer, Tohoku University
Division name
Department of Clinical Oncology
Zip code
Address
4-1 Seiryo-machi, Aoba-ku, Sendai
TEL
022-717-8543
chikashi@tohoku.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Hideki Shimodaira |
Organization
Tohoku Clinical Oncology Research and Education Society (T-CORE)
Division name
Administration Office
Zip code
Address
4-1 Seiryo-machi, Aoba-ku, Sendai
TEL
022-717-8599
Homepage URL
hideki.shimodaira.c4@tohoku.ac.jp
Sponsor or person
Institute
Tohoku Clinical Oncology Research and Education Society (T-CORE)
Institute
Department
Personal name
Funding Source
Organization
Tohoku Clinical Oncology Research and Education Society (T-CORE)
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 04 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Date of protocol fixation
| 2016 | Year | 03 | Month | 30 | Day |
Date of IRB
Anticipated trial start date
| 2016 | Year | 04 | Month | 01 | Day |
Last follow-up date
| 2019 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2016 | Year | 04 | Month | 01 | Day |
Last modified on
| 2017 | Year | 04 | Month | 10 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025079
